News &
Events
Corporate
Overview
Science &
Technology
R & D
Pipeline
Partnering
Investor
Relations
Media
Careers &
Jobs
| Press Releases in | |
 |
|
| 2010, July 22 Cytos' second quarter report. |
|
|
2010, July 15 |
|
| 2010, July 5 Matter Group AG holds 3.4155% of share capital. |
|
| 2010, June 21 Disclosure of shareholding of Cytos Biotechnology Ltd pursuant to Art. 20 SESTA. |
|
| 2010, June 8 Cytos Biotechnology Ltd and Intercell AG close the sale of the platform technology. |
|
| 2010, May 21 Placebo-controlled phase II study shows CYT003-QbG10 is safe and efficacious for the treatment of allergic asthma. |
|
| 2010, May 6 Cytos Biotechnology sells platform technology for the identification of monoclonal antibodies to Intercell. |
|
| 2010, April 30 Harry Welten becomes new CFO at Cytos Biotechnology Ltd. |
|
| 2010, April 23 Constitution of the Board of Directors after the Shareholders’ Meeting 2010. |
|
| 2010, April 22 Annual Shareholders' Meeting of Cytos Biotechnology Ltd: Shareholders approve all resolutions. |
|
| 2010, April 22 Cytos' first quarter report. |
|
| 2010, March 22 Jakob Schlapbach (59) will resign as CFO of Cytos Biotechnology Ltd during the year 2010 and will be proposed to become a member of the board of directors. |
|
| 2010, March 4 Dr. Thomas Hecht succeeds Dr. François L'Eplattenier as chairman of the Board of Directors. |
|
| 2010, February 3 Cytos Biotechnology announces full year 2009 financial results and major developments in 2009. |
|
|
top |
| 2009, November 10 Cytos Biotechnology updates on the development of the hypertension vaccine CYT006-AngQb. |
|
| 2009, November 3 Disclosure of shareholding of Vontobel Fonds Services AG pursuant to Art. 20 SESTA |
|
| 2009, October 22 Cytos' third quarter report. |
|
| 2009, October 15 Interim analysis of an ongoing phase II study with nicotine vaccine shows primary endpoint not achieved. |
|
| 2009, July 31 CYT003-QbG10 monotherapy for the treatment of allergic rhinoconjunctivitis is safe and efficacious in phase IIb study. |
|
| 2009, July 30 Stichting Pensioenfonds ABP has fallen below the notifiable thresholds. |
|
| 2009, July 23 Cytos' second quarter report. |
|
| 2009, June 24 Cytos Biotechnology reports biochemical findings from phase IIa study with hypertension vaccine CYT006-AngQb. |
|
| 2009, June 11 Cytos Biotechnology initiates combined phase I/IIa study with a novel anti-interleukin-1 beta vaccine in patients with type II diabetes mellitus. |
|
| 2009, June 9 Disclosure of shareholding of Cytos Biotechnology Ltd pursuant to Art. 20 SESTA |
|
| 2009, May 13 GLS LP Investment V Ltd has fallen below the notifiable thresholds. |
|
| 2009, May 7 Information relating to the VLP influenza vaccine. |
|
| 2009, April 23 Annual Shareholders' Meeting of Cytos Biotechnology Ltd: Shareholders approve all resolutions. |
|
| 2009, April 22 Cytos' first quarter report. |
|
| 2009, April 21 Cytos Biotechnology initiates phase IIa study with CYT003-QbG10 monotherapy in patients with allergic asthma bronchiale. |
|
| 2009, March 17 Cytos Biotechnology announces alignment of resources following setback in the development of its hypertension vaccine CYT006-AngQb. |
|
| 2009, March 4 InCentive Group holds 3.26% of share capital. |
|
| 2009, February 24 Stichting Pensioenfonds ABP holds 3.01% of share capital. |
|
| 2009, February 11 Cytos Biotechnology announces full year 2008 financial results and annual highlights. |
|
| 2009, January 13 Cytos Biotechnology presents analysis of patient diaries including six month follow-up data from phase II study with CYT003-QbG10 monotherapy for the treatment of allergic diseases. |
|
| 2009, January 5 Pfizer executes commercial license agreements for novel human vaccines based on Cytos Biotechnology's Immunodrug™ technology. |
|
|
top |
| 2008, December 24 Vontobel Fonds Services AG holds 5.64% of share capital. |
|
|
2008, December 9
Cytos Biotechnology starts phase IIb clinical study with CYT003-QbG10 monotheraphy for the treatment of allergic diseases. |
|
| 2008, October 23 Cytos' third quarter report. - including long-term follow-up for the hypertension vaccine CYT006-AngQb. |
|
| October 17, 2008 FIL Limited has fallen below the notifiable thresholds. |
|
| 2008, August 15 Cytos Biotechnology and Pfizer enter into a research, option and license agreement for certain novel vaccines for a defined number of human diseases. |
|
| 2008, July 24 Cytos' second quarter report. - including an update on the two collaborative programs with Novartis in Alzheimer's disease and nicotine addiction. |
|
| 2008, July 10 CYT003-QbG10 monotherapy for the treatment of allergic diseases is safe and efficacious in placebo-controlled phase II study. |
|
| 2008, May 15 HBM BioVentures Ltd. has fallen below the notifiable thresholds. |
|
| 2008, April 24 Annual Shareholders' Meeting of Cytos Biotechnology Ltd: Shareholders approve all resolutions. |
|
| 2008, April 24 Cytos' first quarter report. - including initiation of two phase II studies with CYT006-AngQb in hypertension and a phase IIa study with CYT004-MelQbG10 in malignant melanoma. |
|
| 2008, March 27 Deutsche Bank Aktiengesellschaft has fallen below the notifiable thresholds. |
|
| 2008, March 27 HBM BioVentures Ltd. holds 4.06% of share capital. |
|
| 2008, March 10 InCentive Group holds 6.51% purchase positions and 1.90% sale positions of share capital. |
|
| 2008, March 7 THE LANCET publishes phase IIa results for the hypertension vaccine CYT006-AngQb. |
|
| 2008, February 22 Vontobel Fonds Services AG holds 3.54% of share capital. |
|
| 2008, February 18 Deutsche Bank Aktiengesellschaft holds 2.980% purchase positions and 7.946% sale positions of share capital. |
|
| 2008, February 14 Cytos Biotechnology Announces Full Year 2007 Financial Results and Annual Highlights. |
|
| 2008, February 5 Deutsche Bank Aktiengesellschaft holds 3.407% purchase positions and 8.092% sale positions of share capital. |
|
| 2008, January 24 GLS LP Investment V Ltd holds 4.38% of share capital. |
|
| 2008, January 22 Disclosure of shareholding pursuant to Art. 20 SESTA by Cytos Biotechnology Ltd. |
|
| 2008, January 8 Deutsche Bank Aktiengesellschaft holds 4.102% purchase positions and 7.512% sale positions of share capital. |
|
|
top |
| 2007, December 24 HBM BioVentures Ltd. holds 7.62% of share capital. |
|
| 2007, December 11 Deutsche Bank Aktiengesellschaft holds 15.551% of share capital. |
|
| 2007, December 7 Fidelity holds 3.50% of share capital. |
|
| 2007, November 29 Cytos Biotechnology announces start of two phase II studies with CYT003-QbG10 in allergy indications. |
|
| 2007, November 20 Cytos Biotechnology presents encouraging phase IIa study results for its melanoma vaccine CYT004-MelQbG10. |
|
| 2007, November 6 Presentation of phase IIa results for Cytos Biotechnology's hypertension vaccine at the American Heart Association Scientific Sessions 2007. |
|
| 2007, October 25 Cytos' third quarter report. |
|
| 2007, October 5 Fidelity holds less than 5% of share capital. |
|
| 2007, July 26 Cytos' second quarter report. |
|
| 2007, July 9 Deutsche Bank Aktiengesellschaft holds 5.46% of share capital. |
|
| 2007, July 3 Cytos Biotechnology reports results from phase IIa study with CYT003-QbG10 in patients suffering from atopic dermatitis. |
|
| 2007, June 20 Zurcher Kantonalbank holds less than 5% of share capital. |
|
| 2007, June 17 Hypertension vaccine CYT006-AngQb achieves strong blood pressure reduction during important early morning period when most adverse cardiovascular events occur. |
|
| 2007, May 24 Cytos Biotechnology reports results from a phase I/IIa study with CYT007-TNFQb for the treatment of psoriasis. |
|
| 2007, May 15 Cytos Biotechnology reports positive results from placebo-controlled phase IIa study in patients suffering from house dust mite allergy. |
|
| 2007, April 25 Cytos Biotechnology enters exclusive license agreement with Novartis to develop, manufacture and commercialize novel vaccine for treatment of nicotine addiction. |
|
| 2007, April 25 Cytos' first quarter report. |
|
| 2007, April 25 Cytos Biotechnology's Annual Shareholders' Meeting 2007: Shareholders approve all resolutions. |
|
| 2007, April 23 HBM BioVentures (Cayman) Ltd. holds 14% of share capital. |
|
| 2007, March 30 GLS LP Investment V Ltd. holds less than 5% of share capital. |
|
| 2007, March 13 Placebo-controlled phase IIa study with the immunotherapeutic CYT003-QbG10 shows significant improvement of allergy symptoms in hay fever patients. |
|
| 2007, February 13 Cytos Biotechnology has successfully placed a Convertible Bond of CHF 70 million. |
|
| 2007, February 6 Cytos Biotechnology announces Annual Highlights and Full Year 2006 Financial Results. |
|
| 2007, February 2 Fidelity holds 5.17% of share capital. |
|
| 2007, February 2 Fidelity holds less than 5% of share capital. |
|
| 2007, January 26 Placebo-controlled phase IIa study with hypertension vaccine CYT006-AngQb shows reduction in day-time blood pressure. |
|
|
top |
| 2006, December 20 Cytos Biotechnology updates on outlicensing activities for its phase II Immunodrug™ for treatment of nicotine addiction. |
|
| 2006, November 13 Zurcher Kantonalbank holds 5.11% of share capital. |
|
| 2006, November 7 Phase I/IIa clinical trial with obese individuals shows no effect of CYT009-GhrQb on weight loss. |
|
| 2006, October 26 Cytos Q3 report with new allergy data. |
|
| 2006, September 20 CYT003-QbG10, a novel allergen-independent immunotherapy for allergic diseases, achieves significant efficacy in phase IIa pilot study. |
|
| 2006, July 27 Cytos' second quarter report |
|
| 2006, June 12 Cytos Biotechnology updates on development of allergy vaccine |
|
| 2006, May 23 Fidelity holds 5.08% of share capital. |
|
| 2006, April 27 Shareholders elect Othmar T. Vock to the Board of Directors and approve all resolutions |
|
| 2006, April 27 Cytos' first quarter report. |
|
| 2006, April 25 Vaccine to treat allergic diseases shows significant long-term efficacy in house dust mite allergy patients. |
|
| 2006, February 14 Cytos Biotechnology Announces Annual Highlights and Full Year 2005 Financial Results. |
|
| 2006, February 2 Vaccine to treat nicotine addiction surpasses targeted antibody level in a clinical dose-optimization study. |
|
|
top |
| 2005, December 14 Vaccine candidate CYT005-AllQbQ10 for allergic diseases shows significant efficacy in phase IIa study. |
|
| 2005, December 14 Broadening of allergy portfolio - Start of phase IIa clinical trial with vaccine to treat grass pollen allergy (hay fever). |
|
| 2005, November 17 Vaccine to treat nicotine addiction promotes 12 months continuous abstinence in subjects who achieve high antibody levels. |
|
| 2005, October 27 Cytos' third quarter report. |
|
| 2005, October 20 Melanoma vaccine enters phase IIa clinical trials. |
|
| 2005, August 23 US patent for Immunodrugs™ to treat drug of abuse addiction awarded. |
|
| 2005, July 28 Cytos' second quarter report. |
|
| 2005, June 15 Schroders holds less than 5% of share capital. |
|
| 2005, May 18 Alzheimer's Immunodrug™ starts phase I clinical trial - milestone payment to Cytos. |
|
| 2005, May 14 Vaccine to treat nicotine addiction achieves proof of efficacy. |
|
| 2005, May 11 Obesity vaccine enters clinical trial. |
|
| 2005, April 28 Cytos' first quarter report. |
|
| 2005, April 1 Cytos Biotechnology and Medarex expand their collaboration for new drug targets. |
|
| 2005, March 31 HBM BioVentures Ltd holds more than 5% of share capital due to internal share transaction from HBM BioVentures AG. |
|
| 2005, March 16 Wolfgang A. Renner holds less than 10% of share capital due to capital increase. |
|
| 2005, March 11 Cytos Biotechnology AG to raise CHF 21,4 million net in capital increase. |
|
| 2005, February 14 Annual highlights and full year 2004 financial results. |
|
| 2005, February 14 Positive phase I results for the Immunodrug™ candidate CYT006-AngQb for hypertension. |
|
| 2005, January 6 Pfizer Animal Health and Cytos Biotechnology enter a Research and Commercial License Option Agreement. |
|
|
top |
| 2004, December 7 Cytos Biotechnology initiates a combined phase I/II clinical trial with CYT006-AngQb for treatment of hypertension. |
|
| 2004, December 2 Cytos Biotechnology announces change in Executive Board. |
|
| 2004, December 2 Cytos Biotechnology initiates a phase II clinical trial with CYT005-AllQbG10 for treatment of allergy. |
|
| 2004, October 29 Cytos Biotechnology's third quarter report. |
|
| 2004, October 25 Cytos Biotechnology initiates a phase I/II clinical trial with CYT007-TNFQb for treatment of psoriasis. |
|
| 2004, September 23 Cytos Biotechnology achieves full enrollment for phase II clinical trial with CYT002-NicQb for treating nicotine addiction. |
|
| 2004, September 21 Cytos Biotechnology awarded the third prize of the European BioTechnica Award 2004. |
|
| 2004, September 16 Clinical trial advances Cytos Biotechnology's second Immunodrug™ platform. |
|
| 2004, August 2 Cytos' second quarter report. |
|
| 2004, April 27 Cytos' Annual Shareholders' Meeting: All proposals approved. |
|
| 2004, April 27 Cytos' first quarter report. |
|
| 2004, April 13 Cytos' second Immunodrug™ platform enters clinical development. |
|
| 2004, March 25 Cytos raises CHF 30 million in capital increase. |
|
| 2004, February 3 Cytos enters agreement to supply Alzheimer's Immunodrug™ candidate for early clinical development studies. |
|
| 2004, February 2 Lonza enters a commercial license agreement with Cytos to complement its gene expression system with a new expression technology. |
|
| 2004, January 14 Cytos initiated phase II clinical trial with its Immunodrug™ for nicotine addiction. |
|
|
top |
| 2003, October 31 Increase of free float and controlled expiry of lock-up period. |
|
| 2003, October 27 Cytos' third quarter report. |
|
| 2003, September 10 Novartis executes Commercial License Agreement for Immunodrugs™ against Alzheimer's Disease. |
|
| 2003, August 22 Cytos' second quarter report. |
|
| 2003, July 1 Cytos' Immunodrug™ for smoking addiction successfully completed phase I clinical trial. |
|
| 2003, May 21 Cytos first quarter results. |
|
| 2003, April 30 Cytos' Annual Shareholders Meeting 2003. |
|
| 2003, April 28 Cytos and Novartis extend collaboration agreements. |
|
| 2003, April 23 Cytos' Immunodrug™ for smoking addiction enters phase I clinical trial. |
|
| 2003, March 27 Cytos announces annual highlights and full year financial results 2002. |
|
| 2003, January 21 Interim results exceed expectations in a phase I study with Cytos' Immunodrug™ Qß-Derp1. |
|
| 2003, January 6 Disclosure of a change in the structure of Cytos' shareholders according to the Stock Exchange Law (BEHG Art. 20). |
|
|
top |
| 2002, December 20 Cytos strengthens its clinical & regulatory expertise by election of two new Executive Board members. |
|
| 2002, December 3 Cytos' first Immunodrug™ in phase I. |
|
| 2002, November 29 Cytos' third quarter report and financial statements. |
|
| 2002, November 13 Cytos and Medarex collaborate for new drug targets. |
|
| 2002, October 28 Cytos will be listed tomorrow on the SWX Swiss Exchange. |
|
| 2002, October 22 Cytos announces approval of the merger with Asklia by Cytos' and Asklia's shareholders. |
|
| 2002, September 24 Cytos announces merger with Asklia and listing on the main board of the SWX Swiss Exchange. |
|
| 2002, January 23 Cytos completes CHF 45 million third financing round. |
|
|
top |
| 2001, December 6 Cytos and Millennium initiate collaboration for drug target discovery. |
|
| 2001, October 23 Cytos and Novartis announce major new collaboration for Immunodrugs™. |
|
| 2001, March 13 Cytos Biotechnology AG receives patent for technology that identifies and validates new protein drug candidates. |
|
| 2000, July 25 Cytos Biotechnology receives CHF 50 million in second round of venture capital financing. |
|
| 2000, December 6 Cytos Biotechnology opens subsidiary in Konstanz, Germany. |